Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 24 of the 42 sources its claims cite were checked for support.
Abstract
BACKGROUND: High triglyceride levels are associated with increased cardiovascular risk, but whether reductions in these levels would lower the incidence of cardiovascular events is uncertain. Pemafibrate, a selective peroxisome proliferator-activated receptor α modulator, reduces triglyceride levels and improves other lipid levels. METHODS: In a multinational, double-blind, randomized, controlled trial, we assigned patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia (triglyceride level, 200 to 499 mg per deciliter), and high-density lipoprotein (HDL) cholesterol levels of 40 mg per deciliter or lower to receive pemafibrate (0.2-mg tablets twice daily) or matching placebo. Eligible patients were receiving guideline-directed lipid-lowering therapy or could not receive statin therapy without adverse effects and had low-density lipoprotein (LDL) cholesterol levels of 100 mg per deciliter or lower. The primary efficacy end point was a composite of nonfatal myocardial infarction, ischemic stroke, coronary revascularization, or death from cardiovascular causes. RESULTS: Among 10,497 patients (66.9% with previous cardiovascular disease), the median baseline fasting triglyceride level was 271 mg per deciliter, HDL cholesterol level 33 mg per deciliter, and LDL cholesterol level 78 mg per deciliter. The median follow-up was 3.4 years. As compared with placebo, the effects of pemafibrate on lipid levels at 4 months were -26.2% for triglycerides, -25.8% for very-low-density lipoprotein (VLDL) cholesterol, -25.6% for remnant cholesterol (cholesterol transported in triglyceride-rich lipoproteins after lipolysis and lipoprotein remodeling), -27.6% for apolipoprotein C-III, and 4.8% for apolipoprotein B. A primary end-point event occurred in 572 patients in the pemafibrate group and in 560 of those in the placebo group (hazard ratio, 1.03; 95% confidence interval, 0.91 to 1.15), with no apparent effect modification in any prespecified subgroup. The overall incidence of serious adverse events did not differ significantly between the groups, but pemafibrate was associated with a higher incidence of adverse renal events and venous thromboembolism and a lower incidence of nonalcoholic fatty liver disease. CONCLUSIONS: Among patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia, and low HDL and LDL cholesterol levels, the incidence of cardiovascular events was not lower among those who received pemafibrate than among those who received placebo, although pemafibrate lowered triglyceride, VLDL cholesterol, remnant cholesterol, and apolipoprotein C-III levels. (Funded by the Kowa Research Institute; PROMINENT ClinicalTrials.gov number, NCT03071692.).
Overview
CoChat Summary
TL;DR
In the PROMINENT trial, pemafibrate lowered triglyceride and remnant cholesterol levels but did not reduce cardiovascular events among patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia, low HDL cholesterol, and controlled LDL cholesterol. The trial was stopped early for futility, and pemafibrate was associated with more renal adverse events and venous thromboembolism.
Key findings
- Among 10,497 patients, a primary end-point event occurred in 572 patients in the pemafibrate group and 560 in the placebo group (hazard ratio, 1.03; 95% CI, 0.91 to 1.15; P=0.67), with no apparent effect modification in any prespecified subgroup.
- At 4 months, the relative between-group differences were −26.2% for triglycerides, −25.8% for VLDL cholesterol, −25.6% for remnant cholesterol, and −27.6% for apolipoprotein C-III; apolipoprotein B increased by 4.8%.
- Serious adverse events did not differ significantly overall (1970 vs. 1914; hazard ratio, 1.04; 95% CI, 0.98 to 1.11; P=0.23), but pemafibrate was associated with higher renal adverse events (1463 vs. 1347; hazard ratio, 1.12; 95% CI, 1.04 to 1.20; P=0.004) and venous thromboembolism (71 vs. 35; hazard ratio, 2.05; 95% CI, 1.35 to 3.17; P<0.001), and lower nonalcoholic fatty liver disease (155 vs. 200; hazard ratio, 0.78; 95% CI, 0.63 to 0.96; P=0.02).
Methods
- Multinational, double-blind, randomized, placebo-controlled, event-driven trial conducted at 876 clinical sites in 24 countries; 10,497 patients composed the intention-to-treat population after 41 randomized patients were excluded for Good Clinical Practice violations.
- Eligible patients had type 2 diabetes, fasting triglyceride levels of 200 to 499 mg per deciliter, HDL cholesterol ≤40 mg per deciliter, and LDL cholesterol ≤100 mg per deciliter if they could not receive statins without adverse effects; patients were randomly assigned 1:1 to pemafibrate 0.2-mg tablets twice daily or matching placebo, with median follow-up of 3.4 years.
- The primary efficacy end point was a composite of nonfatal myocardial infarction, ischemic stroke, coronary revascularization, or death from cardiovascular causes; analysis used a likelihood-ratio test based on a proportional-hazards model stratified by sex, history of cardiovascular disease, and baseline statin use, with analysis of covariance for lipid changes.
Limitations
- The paper states that the data cannot rule out the possibility that observed increases in apolipoprotein B and LDL cholesterol levels in the pemafibrate group negated any benefit of reduction in triglyceride or remnant cholesterol levels.
- The trial was terminated early for futility after 75% of the target number of events had accrued, with median follow-up of 3.4 years; the text notes this termination but does not frame it as a limitation.
- Evident from the text: the trial population was 27.5% women and predominantly white (85.4% in the pemafibrate group and 86.4% in the placebo group), which may limit generalizability; the paper does not state this as a limitation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 1 Not valid · 6 Not checked · 62 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The data from the PROMINENT trial are consistent with increased efficiency in conversion of triglyceride-rich lipoprotein remnants to LDL rather than their removal by the liver. 21”
What the sources say
- Disputedcites [21] 21. Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies - a consensus statement from the European Atherosclerosis Society. Eur Heart J 2021; 42: 4791-806. sourceExperimental — accuracy not yet measured
The “Stimulating lipolysis” section says further insights were awaited from PROMINENT, rather than reporting data from it. The paper discusses conversion of remnants to LDL as a possible consequence of more efficient lipolysis, but does not attribute that finding to PROMINENT. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“With the exception of the FIELD trial, all these trials involved patients who were receiving statins.”
What the sources say
- Partly supportedcites [2] 2. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA 2020; 324: 2268-80. sourceExperimental — accuracy not yet measured
The Study Population section (p. 3) says participants in this trial were required to receive statins, supporting the claim for the STRENGTH trial. It does not establish that every other trial under discussion involved statin-treated patients or that FIELD was the sole exception. (LLM, conf=0.84)
- Partly supportedcites [4] 4. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-67. sourceExperimental — accuracy not yet measured
The AIM-HIGH paper reports statin use in its own trial: Table 1, reproduced in the Discussion passage, shows baseline use in 94.4% and 92.8% of the two groups. Our copy does not establish that all the other trials referred to by the citing sentence involved patients receiving statins, or that FIELD was the exception. (LLM, conf=0.83)
- Partly supportedcites [6] 6. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 156374. sourceExperimental — accuracy not yet measured
The Methods (Study Design; page not available) say ACCORD Lipid assigned patients to simvastatin plus fenofibrate or placebo, supporting the claim for this trial. The Discussion (page not available) contrasts ACCORD with FIELD’s statin-therapy drop-in, but does not establish that all the other trials mentioned involved patients receiving statins. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, a previous trial of niacin 4 and two previous trials of fenofibrate 5,6 showed no significant decrease in cardiovascular risk, although triglyceride levels were lowered by 26%, 29%, and 26%, respectively.”
What the sources say
- Partly supportedcites [4] 4. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-67. sourceExperimental — accuracy not yet measured
The Discussion reports no significant reduction in cardiovascular events with extended-release niacin added to intensive statin therapy. However, the Lipid Levels section reports a 28.6% triglyceride decrease at two years in the niacin group, not 26%; Table 2 also gives no 26% decrease at years one or three. Our copy does not provide page numbers for these passages. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“although the findings regarding the latter effect of PPARα agonism are less consistent than those regarding increases in the activity of lipoprotein lipase. 17-19”
What the sources say
- Not checked — no full text of the sourcecites [17] 17. Ginsberg HN. Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives. Am J Med 1987; 83: 66-70. source
- Not checked — no full text of the sourcecites [18] 18. Watts GF, Barrett PH, Ji J, et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003; 52: 803-11. source
- Supportedcites [19] 19. Fabbrini E, Mohammed BS, Korenblat KM, et al. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2010; 95: 2727-35. source
The Discussion (page unavailable) says fibrates differ in their effects on VLDL secretion and clearance, while describing stimulation of lipoprotein lipase activity as a known fibrate effect. The Results likewise show that fenofibrate reduced VLDL-apoB secretion but did not change hepatic VLDL-TG secretion. Together, these passages support the cited comparison in consistency. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Thus, our data further highlight the complexity of lipid mediators of residual risk among patients with insulin resistance who are receiving statin therapy. 6,23-25”
What the sources say
- Supportedcites [6] 6. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 156374. source
The cited ACCORD Lipid paper provides background for the citing authors’ conclusion, rather than evidence about their own PROMINENT data. Its Results (Plasma Lipids and Clinical Outcomes; page unavailable) report lipid changes with fenofibrate added to simvastatin but no significant overall reduction in cardiovascular events; the Discussion describes a possible benefit in a dyslipidemic subgroup. These findings support the point that lipid-related residual risk in statin-treated patients with type 2 diabetes is complex. (LLM, conf=0.85)
- Supportedcites [23] 23. Elam MB, Ginsberg HN, Lovato LC, et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol 2017; 2: 370-80. source
The reference supports the cited background point, not the citing authors’ statement about their own PROMINENT data. The Introduction describes uncertain cardiovascular benefit from targeting triglycerides and HDL-C in statin-treated patients with type 2 diabetes; the Discussion describes mixed trial results, and the Results report a neutral overall fenofibrate effect but possible benefit in a dyslipidemic subgroup. (LLM, conf=0.88)
- Partly supportedcites [24] 24. Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes Metab 2019; 21: 366-71. sourceExperimental — accuracy not yet measured
The Discussion reports that triglyceride levels were associated with residual cardiovascular events in statin-treated patients with diabetes despite controlled LDL cholesterol, supporting the background point about lipid-related residual risk. The study concerns patients with diabetes, not the broader population of patients with insulin resistance. The citing authors’ statement about what their own data highlight is not attributed to this source. (LLM, conf=0.82)
- Partly supportedcites [25] 25. Zhao Y, Xiang P, Coll B, López JAG, Wong ND. Diabetes associated residual atherosclerotic cardiovascular risk in statin-treated patients with prior atherosclerotic cardiovascular disease. J Diabetes Complications 2021; 35: 107767. Copyright © 2022 Massachusetts Medical Society. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report residual ASCVD risk in statin-treated patients with diabetes and identify lipoprotein(a) as a predictor of recurrent events. This supports a role for lipid-related risk, but the paper studies diabetes rather than insulin resistance broadly and does not establish lipid mediation of that residual risk. The citing sentence’s reference to “our data” is the citing authors’ own conclusion, not a claim about this source. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
44 more claims
Create a free account to see all 81 claims and every source verdict.
- It may state two separate claims as one. 16
- Probably not a substantial claim. 22
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At a median follow-up of 3.4 years, pemafibrate lowered triglycerides by − 26%, VLDL by − 26%, remnant cholesterol by − 26% and ApoC-III by − 28% compared with placebo.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [180]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the PROMINENT trial, in people with type 2 diabetes and elevated triglycerides (≥200 mg/dL and low HDL [≤40 mg/dL]), pemafibrate 0.2 mg twice daily reduced triglycerides by 26% but did not reduce the risk of the primary outcome of nonfatal MI, nonfatal stroke, hospitalization for unplanned coronary revascularization, or cardiovascular death (151).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [151]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, pemafibrate did not significantly reduce the risk of MACE (HR 1.03, 95% CI 0.91–1.15).”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [180]
The cited source says what the claim attributes to it.
In the citing paper
“Although pemafibrate significantly reduced TGs (–26.2%), VLDL-C, and remnant cholesterol, it did not reduce MACE compared to placebo, likely due to a lack of effect on apoB-containing particle number and modest increases in LDL-C [64, 65].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [64]
The cited source says what the claim attributes to it.
In the citing paper
“Although pemafibrate significantly reduced TGs (–26.2%), VLDL-C, and remnant cholesterol, it did not reduce MACE compared to placebo, likely due to a lack of effect on apoB-containing particle number and modest increases in LDL-C [64, 65].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [64]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Effects on Lipid Levels and Other Key Biomarkers · p. 8
“Pemafibrate, as compared with placebo, also had similar effects on changes from baseline to 4 months and over time on levels of measured very-low-density lipoprotein (VLDL) cholesterol (-25.8%)”
§ Effects on Lipid Levels and Other Key Biomarkers · p. 7
“| VLDL cholesterol level, calculated - mg/dl‡ | VLDL cholesterol level, calculated - mg/dl‡ | VLDL cholesterol level, calculated - mg/dl‡ | VLDL cholesterol level, calculated - mg/dl‡ |”
Citations
Cites
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Self-citationNicholls, S. J., Lincoff, A. M., Garcia, M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., et al. (2020) · JAMA · doi:10.1001/jama.2020.22258 · Cited by 1,028
Self-citationGinsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
Self-citationEffects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927
Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.09.011 · Cited by 319
Self-citationCombination lipid therapy in type 2 diabetes
(2010) · New England Journal of Medicine · doi:10.1056/nejmc1006407 · Cited by 245
Cited by
Items 101–200 of 728
Lauwers, C., Bruyn, L. D., & Langouche, L. (2023) · Intensive Care Medicine Experimental · doi:10.1186/s40635-023-00570-y · Cited by 39
Wadström, B. N., Pedersen, K. M., Wulff, A. B., & Nordestgaard, B. G. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.320175 · Cited by 35
Self-citationFemale sex-specific considerations to improve rigor and reproducibility in cardiovascular research
Chang, D. H., Dumanski, S. M., & Ahmed, S. B. (2022) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00462.2022 · Cited by 36
Liu, Y., Wang, W., Cui, X., Lyu, J., & Xie, Y. (2024) · Stroke · doi:10.1161/strokeaha.123.044424 · Cited by 32
Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD
Vitulo, M., Gnodi, E., Rosini, G., Meneveri, R., Giovannoni, R., & Barisani, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612748 · Cited by 37
Deerochanawong, C., Kim, S. G., & Chang, Y.-C. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0168 · Cited by 31
“However, the trial reported a lower incidence of NAFLD with pemafibrate treatment [46].”
Potential therapeutic strategies for MASH: from preclinical to clinical development
Xie, Z., Li, Y., Cheng, L., Huang, Y., Rao, W., Shi, H., & Li, J. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae029 · Cited by 33
Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S)
Strandberg, T. E., Kovanen, P. T., Lloyd‐Jones, D. M., Raal, F. J., Santos, R. D., & Watts, G. F. (2024) · The Lancet · doi:10.1016/s0140-6736(24)02089-0 · Cited by 30
Self-citationChapman, M. J., Packard, C. J., Björnson, E., Ginsberg, H. N., & Borén, J. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120529 · Cited by 39
Self-citationElías-López, D., Doi, T., Nordestgaard, B. G., & Kobylecki, C. J. (2023) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000999 · Cited by 40
Self-citation[Incisional hernia after surgery for abdominal aortic aneurysm].
Augestad, K. M., Wilsgaard, T., & Solberg, S. K. (2002) · Tidsskrift for Den Norske Laegeforening · Cited by 41
Jones, J. E., Tang, K. S., Barseghian, A., & Wong, N. D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12237432 · Cited by 36
Hirano, T. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.14398 · Cited by 42
“The PROMINENT study 141 is a large-scale study of more than 10,000 high-risk T2D patients with mixed dyslipidemia characterized by moderate hypertriglyceridemia and low HDL-C.”
Galli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 52
“…plasma are an independent marker of increased ischaemic risk, pharmacological interventions that lower triglyceride levels, such as extended-release niacin, omega-3 fatty acids and fibrates, have not consistently demonstrated reductions in cardiovascular events when used alongside statins 249,250 .”
Remnant cholesterol in atherosclerotic cardiovascular disease: A systematic review and meta-analysis
Delialis, D., Georgiopoulos, G. A., Aivalioti, E., Konstantaki, C., Oikonomou, E., Bampatsias, D., Mavraganis, G., Vardavas, C. I., Liberopoulos, E. N., Stellos, K., et al. (2023) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2023.04.007 · Cited by 33
Drexel, H., Tamargo, J. L., Kaski, J. C., Lewis, B. S., Saely, C. H., Fraunberger, P., Dobrev, D., Komiyama, M., PLATTNER, T., Agewall, S., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad044 · Cited by 34
Luo, Y., & Peng, D. (2023) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484231189597 · Cited by 32
New Insights Into the Treatment of Hyperlipidemia: Pharmacological Updates and Emerging Treatments
Abbasi, S., Khan, A. A., & Choudhry, M. W. (2024) · Cureus · doi:10.7759/cureus.63078 · Cited by 49
“However, the study was halted prematurely due to lack of effectiveness [50].”
Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review
Zimodro, J. M., Rizzo, M., & Gouni‐Berthold, I. (2025) · Pharmaceuticals · doi:10.3390/ph18020147 · Cited by 32
Muro, F. M. D., Vogel, B., Sartori, S., Bay, B., Oliva, A., Feng, Y., Krishnan, P., Sweeny, J. M., Gitto, M., Smith, K. F., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf112 · Cited by 36
Current, emerging, and potential therapies for non-alcoholic steatohepatitis
Yang, Z. L., & Wang, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1152042 · Cited by 32
Spagnuolo, C. M., & Hegele, R. A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2206015 · Cited by 28
Katsiki, N., Filippatos, T. D., Vlachopoulos, C. V., Panagiotakos, D. B., Milionis, H. J., Tselepis, A. D., Garoufi, A., Rallidis, L. S., Richter, D. J., Nomikos, T., et al. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.01.004 · Cited by 29
What Causes Premature Coronary Artery Disease?
Le, A., Peng, H., Golinsky, D., Scipio, M. D., Lali, R., & Paré, G. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01200-y · Cited by 38
“Furthermore, results of clinical trials testing the effects of TG lowering agents on cardiovascular events have been mostly null [61–65], suggesting that only certain pathways leading to high TG levels are associated with CAD, while others are not.”
Landscape of Statin as a Cornerstone in Atherosclerotic Cardiovascular Disease
Yang, C., Wu, Y., Qian, J., & Li, J. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2412373 · Cited by 31
Remnant cholesterol as a new lipid-lowering target to reduce cardiovascular events
Raggi, P., Becciu, M. L., & Navarese, E. P. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000921 · Cited by 27
Akivis, Y., Alkaissi, H. R., McFarlane, S. I., & Bukharovich, I. F. (2024) · Current Cardiology Reviews · doi:10.2174/011573403x272750240109052319 · Cited by 34
“The PROMINENT study, however, re-ported that Pemafibrate failed to lower cardiovascular mortality despite its effective triglyceride, VLDL-C, and remnant cholesterol-lowering properties [64].”
Tanaka, A., & Node, K. (2024) · Hypertension Research · doi:10.1038/s41440-024-01737-0 · Cited by 29
Remnant Cholesterol and Residual Risk of Atherosclerotic Cardiovascular Disease
Li, X., Li, Z.-F., & Wu, N. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm25985 · Cited by 30
“…with hyper-triglyceridemia and diabetes treated with statins, observed a 26.2% reduction in triglyceride levels and a 25.6% reduction in RC at 4 months; however, cardiovascular event incidence did not differ significantly from placebo-treated patients (HR: 1.03, 95% CI: 0.91–1.15; p = 0.67) [54].”
InfluentialEffect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies
Ray, K. K., Linnebjerg, H., Michael, L. F., Shen, X. P., Ma, X., Lim, S., Zhen, Y., Dudek, H., Abrams, M., Saxena, U. H., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.005 · Cited by 32
Self-citationZimerman, A., Wiviott, S. D., Park, J., Murphy, S. A., Ran, X., Bramson, C., Curto, M., Ramos, V., Jevne, A., Kuder, J., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae090 · Cited by 29
Hypercholesterolemia and inflammation—Cooperative cardiovascular risk factors
Gallo, A., Goff, W. L., Santos, R. D., Fichtner, I., Carugo, S., Corsini, A., Sirtori, C. R., & Ruscica, M. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14326 · Cited by 32
Self-citationYang, Y., Kim, H., Kim, S., & Moon, M. K. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.12 · Cited by 30
Fibrates and the risk of cardiovascular outcomes in chronic kidney disease patients
Goto, H., Iseri, K., & Hida, N. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad248 · Cited by 24
Dyslipidemia: A Narrative Review on Pharmacotherapy
de Oliveira, L. D., de Assis, A. C. R., Giraldez, V. Z. R., Scudeler, T. L., & Soares, P. R. (2024) · Pharmaceuticals · doi:10.3390/ph17030289 · Cited by 30
“The Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides In Patients with Diabetes (PROMINENT) was conducted to evaluate the role of fibrate additive therapy in reducing the residual risk of ASCVD in patients with high TGs [98].”
MethodVijayaraghavan, K., Baum, S. J., Desai, N. R., & Voyce, S. J. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1308173 · Cited by 26
Taskinen, M., Matikainen, N., Björnson, E., Söderlund, S., Inkeri, J., Hakkarainen, A., Parviainen, H., Sihlbom, C., Thorsell, A., Andersson, L. K., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-06008-0 · Cited by 25
Liu, S., Zhang, D., Ju, J., Wang, A., Du, T., Chen, X., Song, Y., Gao, Z., & Xu, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1260764 · Cited by 24
Lipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis
Masson, W., Barbagelata, L., Lobo, M., Nogueira, J. P., & Handelsman, Y. (2025) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.12.016 · Cited by 23
Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management
Iatan, I., Mancini, G. B. J., Yeoh, E., & Hegele, R. A. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2215982 · Cited by 29
“Fibrates do not lower LDL-C or apo B and RCTs of ASCVD outcomes have been neutral [111].”
BackgroundANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
Chan, D. C., & Watts, G. F. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000920 · Cited by 24
Fenofibrate Attenuates Renal Tubular Cell Apoptosis by Up-Regulating MCAD in Diabetic Kidney Disease
Tang, C., Deng, X., Qu, J., Miao, Y., Tian, L., Zhang, M., Li, X., Sun, B., & Chen, L. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s405266 · Cited by 24
“However, a multinational, double-blind, randomized, controlled trial revealed that the incidence of adverse renal events was not lower among those who received pemafibrate than among those who received placebo among patients with type 2 diabetes, although pemafibrate lowered triglyceride, VLDL cholesterol, remnant cho…”
BackgroundMolecular Regulation and Therapeutic Targeting of VLDL Production in Cardiometabolic Disease
Burks, K. H., Stitziel, N. O., & Davidson, N. O. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.101409 · Cited by 27
Aggarwal, R., Bhatt, D. L., Steg, P. G., Miller, M. J., Brinton, E. A., Dunbar, R. L., Ketchum, S. B., Tardif, J., Martens, F. M. A. C., Ballantyne, C. M., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038656 · Cited by 23
Self-citationTriglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease Risk
Duell, P. B. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.11.013 · Cited by 23
Yang, Y., Kim, H., Kim, S., Moon, M. K., & Korean Society of Lipid and Atherosclerosis (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0448 · Cited by 26
“7% of the study population were already receiving statins, even though it significantly reduced triglyceride, verylow-density lipoprotein cholesterol, measured remnant cholesterol, and apolipoprotein C-III levels [51].”
BackgroundUpdates in Small Interfering RNA for the Treatment of Dyslipidemias
Carugo, S., Sirtori, C. R., Gelpi, G., Corsini, A., Tokgözoğlu, L. S., & Ruscica, M. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01156-5 · Cited by 24
“…and TRL remnants, and increased risk of ASCVD [14], the results of the PROMINENT (The Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycer-ides in Patients with Diabetes) study cast doubts whether lowering TG levels per se would also lower the incidence of cardiovascular events [77].”
BackgroundWang, J., Jin, R., Jin, X., Wu, Z., Zhang, H., Han, Z., Xu, Z., Liu, Y., Zhao, X., Guo, X., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029352 · Cited by 21
Worldwide Increasing Use of Nonfasting Rather Than Fasting Lipid Profiles
Langsted, A., & Nordestgaard, B. G. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvae046 · Cited by 24
Self-citationLi, Z., Yu, C., Zhang, H., Chen, R., Zhao, Y., & Zheng, Z. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02537-z · Cited by 20
HFpEF and MASLD: converging mechanisms and clinical implications
Capone, F., Häseli, S. P., Liu, L., Strocchi, S., Langenberg, C., Lusis, A. J., Pietzner, M., Muoio, D. M., Rider, O. J., Raman, B., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01257-z · Cited by 37
“Data suggest that treatment with pemafibrate, a selective PPARα modulator, was associated with lower rates of MASLD diagnoses compared with placebo 421 , whereas statins were linked to lower prevalence of MASH and MASLD in pooled analyses 422 .”
Hypertriglyceridemia and Atherosclerotic Carotid Artery Stenosis
Miura, Y., & Suzuki, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416224 · Cited by 22
Fuior, E. V., Zvintzou, E., Filippatos, T. D., Giannatou, K., Mparnia, V., Simionescu, M., Gafencu, A. V., & Kypreos, K. E. (2023) · Biomedicines · doi:10.3390/biomedicines11102696 · Cited by 28
Guo, J., Miao, G., Zhang, W., Shi, H., Lai, P., Xu, Y., Zhang, L., Chen, G., Han, Y., Zhao, Y., et al. (2024) · Theranostics · doi:10.7150/thno.91084 · Cited by 22
“…associated with the metabolic disorders, such as Ivyspring International Publisher obesity, type II diabetes, nonalcoholic fatty liver disease (NAFLD) and acute pancreatitis [1-3], which recently has been recognized as an independent causal risk factor of cardiovascular disease (CVD) [4, 5].”
BackgroundExpanding the triglyceride range in clinical trials: therapeutic opportunities
Nordestgaard, A. T., Pradhan, A. D., Everett, B. M., MacFadyen, J. G., Bhatt, D. L., Visseren, F. L. J., Libby, P., Santos, R. D., Nissen, S. E., Nordestgaard, B. G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf074 · Cited by 20
Self-citationDrugs targeting peroxisome proliferator-activated receptors
Xie, Z., Xin, J., Huang, C.-J., & Liao, C. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104318 · Cited by 25
Muratore, E., Leardini, D., Baccelli, F., Venturelli, F., Cerasi, S., Zanaroli, A., Lanari, M., Prete, A., Masetti, R., & Zama, D. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1075778 · Cited by 27
“Metaanalysis was not performed due to the heterogeneity of the four included studies regarding populations, interventions and outcomes analyzed (64).”
BackgroundBanach, M., & Surma, S. (2023) · Archives of Medical Science · doi:10.5114/aoms/166256 · Cited by 30
“And this approach should not be changed despite the negative results of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study, in which pemafibrate failed to improve cardiovascular outcomes [21].”
InfluentialFularski, P., Hajdys, J., Majchrowicz, G., Stabrawa, M., Młynarska, E., Rysz, J., & Franczyk, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031637 · Cited by 28
“A study by Kastelein et al. [157] has assessed the efficacy of anacetrapib in combination with statin therapy in patients with HeFH and found that it reduced LDL-C by nearly 40%.”
BackgroundDoi, T., Langsted, A., & Nordestgaard, B. G. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117556 · Cited by 25
Self-citationGurevitz, C., & Rosenson, R. S. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae388 · Cited by 19
Impact of Remnant Cholesterol on Cardiovascular Risk in Diabetes
Elías-López, D., Wadström, B. N., Vedel‐Krogh, S., Kobylecki, C. J., & Nordestgaard, B. G. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01555-1 · Cited by 18
“The Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) trial investigated the use of pemafibrate compared to placebo on risk of ASCVD or death from cardiovascular causes in individuals with type 2 diabetes [16].”
Self-citationBallantyne, C. M., Gaudet, D., Rosenson, R. S., Hegele, R. A., Zhou, R., Melquist, S., Hellawell, J. L., & Leeper, N. J. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.496 · Cited by 23
Eicosapentaenoic acid vs. docosahexaenoic acid for the prevention of cardiovascular disease
Sweeney, T. E., Gaine, S. P., & Michos, E. D. (2023) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000796 · Cited by 18
Xu, W., Zhao, H., Gao, L., Guo, L., Liu, J., Li, H., Sun, J., Xing, A., Chen, S., Wu, S., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1148203 · Cited by 21
Present and Future of Dyslipidaemia Treatment—A Review
Merćep, I., Vujević, A., Strikić, D., Radman, I. B., Pećin, I., & Reiner, Ž. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185839 · Cited by 25
Chan, D. C., & Watts, G. F. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01254-y · Cited by 23
“However, these agents only have a modest effect on LDL-cholesterol and apoB in patients with moderately elevated HTG which may not lead to achieve a clinical benefit, as exemplified by the results of the PROMINENT trial [ 71].”
Gan, L., Zhao, J., Yao, P., Christopher, T. A., Lopez, B., Lau, W. B., Koch, W. J., Gao, E., Ma, X., & Wang, Y. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103443 · Cited by 24
“In recent large-scale clinical trials, strict glycemic or lipid controls failed to demonstrate cardiovascular mortality benefits in diabetic patients [3 – 5].”
Karakasis, P., Patoulias, D., Rizzo, M., Fragakis, N., & Mantzoros, C. S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16258 · Cited by 24
“69 This finding introduces a new potential option for lowering plasma TGs and RC concentrations.”
Jo, S. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.3.247 · Cited by 20
Remnant cholesterol in the era of intensive lipid-lowering therapies
Wadström, B. N., Wulff, A. B., Pedersen, K. M., & Nordestgaard, B. G. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad298 · Cited by 17
Self-citationUpdates on dyslipidemia in patients with diabetes
Ide, S., Maezawa, Y., & Yokote, K. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14042 · Cited by 24
Self-citationDugré, N., Lindblad, A. J., Perry, D., Allan, G. M., Braschi, É., Falk, J., Froentjes, L. S., Garrison, S., Kirkwood, J. E. M., Korownyk, C. S., et al. (2023) · Canadian Family Physician · doi:10.46747/cfp.6910701 · Cited by 25
Remnant cholesterol traits and risk of stroke: A multivariable Mendelian randomization study
Wu, Z., Jiang, Y., Guo, Z., Li, P., Zheng, Y., Wang, Y., Zhang, H., Balmer, L. A., Li, X., Tao, L., et al. (2024) · PNAS Nexus · doi:10.1093/pnasnexus/pgae033 · Cited by 18
Lee, J., Gilliland, T., Koyama, S., Nakao, T., Dron, J. S., Lannery, K., Wong, M. Y., Peloso, G. M., Hornsby, W., & Natarajan, P. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.321282 · Cited by 21
Ma, X., Chu, H., Sun, Y., Cheng, Y., Zhang, D., Zhou, Y., Liu, X., & Wang, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-69158-0 · Cited by 26
“Unfortunately, randomized trials of therapies that primarily lowered triglycerides have not consistently shown a reduction in adverse cardiovascular events 41,42 .”
BackgroundMedications for Lipid Control: Statins vs Newer Drugs
McPherson, R., Adreak, N., & Sharma, A. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.05.004 · Cited by 33
Doi, T., Nordestgaard, B. G., & Langsted, A. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000799 · Cited by 18
Self-citationVLDL receptor gene therapy for reducing atherogenic lipoproteins
Krauss, R. M., Lu, J. T., Higgins, J. J., Clary, C. M., & Tabibiazar, R. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101685 · Cited by 18
“However, the recent PROMINENT trial of pemafibrate, a more potent fibrate drug, in patients with type 2 diabetes mellitus, mild-to-moderate hypertriglyceridemia, and low levels of HDLC while treated with statins, found no effect on the primary CVD endpoint despite significant reductions of TG, VLDL cholesterol, remnan…”
BackgroundInfluentialLarge-scale metabolomic profiling and incident non-alcoholic fatty liver disease
Gagnon, É., Manikpurage, H. D., Mitchell, P. L., Girard, A. S., Gobeil, É., Bourgault, J., Bégin, F., Marette, A., Thériault, S., & Arsenault, B. J. (2023) · iScience · doi:10.1016/j.isci.2023.107127 · Cited by 16
“4 years incident NAFLD by 22% when compared to placebo in 10,497 patients with type 2 diabetes.(30) These studies, combined with the results of our study suggest that the mechanism of triglyceride-reducing drugs may be important for the prevention and/or treatment of NAFLD.”
ResultKurooka, N., Eguchi, J., & Wada, J. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14056 · Cited by 17
Wang, Y., Zhang, L., Zhang, W., Tang, M., Cui, H., Wu, X., Zhao, X., Chen, L., Yan, P., Yang, C., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04509-5 · Cited by 20
HDL as a Treatment Target: Should We Abandon This Idea?
Bègue, F., Apalama, M. L., Lambert, G. C., & Meilhac, O. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01176-1 · Cited by 16
“[46].”
Macrophage fatty acid oxidation in atherosclerosis
Xiao, S., Qi, M., Zhou, Q., Gong, H.-Q., Wei, D., Wang, G., Feng, Q., Wang, Z., Liu, Z., Zhou, Y., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116092 · Cited by 27
When cardiovascular medicines should be discontinued
Krychtiuk, K. A., Gersh, B. J., Washam, J. B., & Granger, C. B. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae302 · Cited by 21
Lessons from PROMINENT and prospects for pemafibrate
Fruchart, J.-C., Fruchart-Najib, J., Yamashita, S., Libby, P., Yokote, K., Kodama, T., Tomita, Y., Ridker, P. M., Hermans, M. P., & Zambon, A. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02305-z · Cited by 16
“…adverse cardiovascular events, a composite of nonfatal myocardial infarction, ischaemic stroke, coronary revascularization, or death from cardiovascular causes (hazard ratio 1.03, 95% confidence interval [CI], 0.91 to 1.15), with no apparent effect modification in any prespecified subgroup [26].”
BackgroundMethodResultInfluentialSelf-citationZahger, D., Schwartz, G. G., Du, W., Szarek, M. J., Bhatt, D. L., Bittner, V., Budaj, A., Díaz, R., Goodman, S. G., Jukema, J. W., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.035 · Cited by 22
Hvid, K., Balling, M., Afzal, S., & Nordestgaard, B. G. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf203 · Cited by 15
Self-citationSamson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 35
Takeda, Y., Sakuma, I., Hiramitsu, S., Okada, M., Ueda, S., & Sakurai, M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1094100 · Cited by 17
“Just recently, the results of the PROMINENT trial, which prospectively examined the preventive effects of pemafibrate on cardiovascular events among patients with type 2 diabetes, mild-tomoderate hypertriglyceridemia, and low HDL-C and LDL-C levels were published (72).”
ResultBiomedical Advances in ABCA1 Transporter: From Bench to Bedside
Choi, H. Y., Choi, S., Iatan, I., Ruel, I. L., & Genest, J. J. (2023) · Biomedicines · doi:10.3390/biomedicines11020561 · Cited by 16
Verma, S., David, J., Leiter, L. A., Michelsen, M. M., Rasmussen, S., & Bhatt, D. L. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15081 · Cited by 17
Self-citationYang, X. H., Tu, Q. M., Li, L., Guo, Y. P., Wang, N. S., & Jin, H. M. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117187 · Cited by 18
Kumarapperuma, H., Chia, Z.-J., Malapitan, S. M., Wight, T. N., Little, P. J., & Kamato, D. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.118552 · Cited by 21
de Souza, M. D. M., Mendes, B. X., Defante, M. L. R., Morais, B. A. D. A. D. H., Martins, O. C., Prizão, V. M., & Romaniello, G. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156187 · Cited by 16
Bergmark, B. A., Marston, N., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Kang, Y. M., Murphy, S. A., Zhang, S. M., Lu, M. T., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.02.022 · Cited by 17
Lu, J., Wang, Z., Zhang, J., Jiao, F., Zou, C., Han, L., & Jiang, G. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100528 · Cited by 15
Genetic associations of protein-coding variants in venous thromboembolism
He, X., Wu, B., Liu, Y., Yu, C., Deng, Y., Li, Z.-Y., Fei, C.-J., Liu, W., Ge, Y., Kang, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47178-8 · Cited by 14
Colchicine for the Prevention of Cardiovascular Disease: Potential Global Implementation
Zhang, R. S., Weber, B., Garaygordobil, D. A., & Garshick, M. S. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02049-y · Cited by 20
“Previous trials illustrate that patients with well-controlled LDL-C fare worse when inflammatory biomarkers, such as high-sensitivity C-reactive protein (hs-CRP), remain elevated [3–5].”
The effect of lipid-lowering therapy on lipid-related residual risk factors: a prospective study
Li, Z., Gao, Y., Lu, Q., Yin, Z., Zhang, S., Zhang, W., Sui, Y., Xu, Y.-L., Li, J., Dou, K., et al. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02078-0 · Cited by 15
“…findings from the large-scale phase III PROMINENT trial indicated that for individuals with high TG and diabetes, pemafibrate did not result in a decreased risk of cardiovascular events or mortality even though it led to a reduction of approximately 20–30% each in TG, RC, VLDL-C, and apoCIII [43].”
Background
Metadata
- Authors
- Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., Brinton, E. A., Eckel, R. H., Elam, M. B., Felicio, J. S., Ginsberg, H. N., Goudev, A., Ishibashi, S., Joseph, J., Kodama, T., Koenig, W., Leiter, L. A., Lorenzatti, A. J., Mankovsky, B., Marx, N., Nordestgaard, B. G., Páll, D., Ray, K. K., Santos, R. D., Soran, H., Susekov, A., Tendera, M., Yokote, K., Paynter, N. P., Buring, J. E., Libby, P., & Ridker, P. M.
- Affiliations
- From the Center for Cardiovascular Disease Prevention, Division of Preventive Medicine (A.D.P., R.J.G., J.G.M., E.S.Z., B.M.E., N.P.P., J.E.B., P.M.R) and the Division of Cardiovascular Medicine (B.M.E.,P.L., P.M.R.), Brigham and Women’s Hospital, the Division of Cardiovascular Medicine, Veteran Affairs Boston Health Care System (A.D.P., J.J.), and Kowa Pharma Development (R.O.) — all in Boston; University of Lille, Lille (J.-C.F.) and the Department of Neurology and Stroke Center, Paris Cité University, Paris (P.A.) — both in France; Kowa Research Institute, Morrisville, NC (S.E.C.); the Division of Lipidology, Department of Medicine, University of Cape Town, Cape Town, South Africa (D.J.B.); Utah Lipid Center, Salt Lake City (E.A.B.); the University of Colorado School of Medicine, Aurora (R.H.E.); the University of Tennessee Health Science Center, Memphis (M.B.E.); the Division of Endocrinology, Universitário Hospital João de Barros Barreto, Belém (J.S.F.), and the Heart Institute (InCor), University of ...
- Brigham and Women's Hospital (US)
- University of Copenhagen (DK)
- ORCID
- Everett, Brendan M.
- Amarenco, Pierre
- Blom, Dirk J.
- Brinton, Eliot A.
- Eckel, Robert H.
- Elam, Marshall B.
- Ginsberg, Henry N.
- Goudev, Assen
- Ishibashi, Shun
- Joseph, Jacob
- Kodama, Tatsuhiko
- Leiter, Lawrence A.
- Lorenzatti, Alberto J.
- Mankovsky, Boris
- Marx, Nikolaus
- Nordestgaard, Børge G.
- Páll, Dénes
- Ray, Kausik K.
- Santos, Raul D.
- Soran, Handrean
- Susekov, Andrey
- Yokote, Koutaro
- Paynter, Nina P.
- Buring, Julie E.
- Libby, Peter
- Ridker, Paul M
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-11-24
- Volume
- 387
- Issue
- 21
- Pages
- 1923-1934
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4308367139
- Semantic Scholar
- 2a5f509a3e50569b803a22d0dee824c145e73e75
- Cited by
- 749
- References
- 25
- Citations by year
- 2026: 153 · 2025: 185 · 2024: 191 · 2023: 208 · 2022: 10
- FWCI
- 142.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Kowa Research Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- pemafibrate, hypertriglyceridemia, type 2 diabetes, PPARα agonist, triglyceride lowering, cardiovascular risk reduction, cardiovascular events, HDL cholesterol, remnant cholesterol, apolipoprotein C-III, apolipoprotein B, VLDL cholesterol, renal adverse effects, venous thromboembolism, lipid-lowering therapy, statin intolerance
- MeSH terms
- Heart Disease Risk Factors, Hypolipidemic Agents, Benzoxazoles, Butyrates, Cardiovascular Diseases, Cholesterol, Diabetes Mellitus, Type 2, Double-Blind Method, Humans, Hyperlipidemias, Cholesterol, HDL, Cholesterol, LDL, Risk Factors, Triglycerides, Hypertriglyceridemia, Hydroxymethylglutaryl-CoA Reductase Inhibitors, PPAR alpha, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.